Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Application of the AI Platform iLN Based on DeepSeek in the Teaching of Lupus Nephritis

Aim: To evaluate the application effect of the teaching platform iLN in the teaching of lupus nephritis, aiming to provide practical experience and evidence-based support for the implementation of generative AI technology in professional medical education. Method: Based on the DeepSeek large language model, the investigators developed "iLN" - an interactive teaching platform for lupus nephritis. This platform integrates the latest authoritative textbooks, clinical guidelines, pathological atlases, and real clinical cases, and includes seven core modules, such as "case interaction", "knowledge teaching", and "AI question answering". The investigators conducted a randomized controlled trial (RCT) on 50 fourth-year undergraduate students from Nanjing University School of Medicine to evaluate the effectiveness of the iLN platform compared to traditional teaching methods. The teaching effect was evaluated through objective test scores and questionnaires about student satisfaction and platform usability.

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Nanjing UniversityUpdated: Jul 16, 2026Locations: 1
Eligibility criteria

As a student majoring in clinical medicine [+1]

Inability to understand, read, or communicate in Chinese [+2]

Status: Not yet recruiting

Intrauterine G-CSF Infusion for Thin Endometrium

Thin endometrium is a condition in which the lining of the uterus is too thin during preparation for embryo transfer. This may reduce the chance of pregnancy and live birth in patients undergoing frozen-thawed embryo transfer. This study will evaluate whether intrauterine infusion of granulocyte colony-stimulating factor, also called G-CSF, can improve pregnancy outcomes in patients with thin endometrium. Participants will be randomly assigned to one of two groups. The experimental group will receive mild endometrial stimulation followed by intrauterine infusion of G-CSF 300 μg. The control group will receive the same mild endometrial stimulation followed by intrauterine infusion of normal saline. Both groups will then continue standard endometrial preparation for frozen-thawed embryo transfer. The main outcome of the study is the live birth rate. The study will also assess endometrial thickness, endometrial blood flow, clinical pregnancy rate, miscarriage rate, and safety outcomes, including adverse events, pregnancy complications, fetal malformations, and neonatal birth defects. Participants will be followed from enrollment through embryo transfer, pregnancy assessment, and delivery. This is a single-center, prospective, randomized controlled trial conducted at Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School. The planned sample size is 620 participants.

Participants needed: 620
Trial details
Phase: Phase 3Age: 18-39Biological sex: FemaleType: InterventionalSponsor: Nanjing UniversityUpdated: Jul 9, 2026
Eligibility criteria

Female patients aged 18 to <40 years. [+5]

Uterine diseases or conditions that may affect the uterine cavity, including int... [+3]

Status: Recruiting

Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment

This randomized controlled trial aims to evaluate whether supplementation with exogenous luteinizing hormone (LH) can improve embryo quality in patients undergoing in vitro fertilization (IVF) with a long gonadotropin-releasing hormone agonist (GnRH-a) protocol who have excessive suppression of LH. Eligible participants will be randomly assigned to receive either exogenous LH supplementation or standard care. The primary outcome is embryo quality, and secondary outcomes include pregnancy rates and safety assessments. The study is conducted at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University.

Participants needed: 590
Trial details
Age: 20-37Biological sex: FemaleType: InterventionalSponsor: Nanjing UniversityUpdated: Aug 19, 2025Locations: 1
Eligibility criteria

Women aged 20 to 37 years (inclusive). Diagnosed with infertility and undergoing...

Polycystic ovary syndrome (PCOS). History of recurrent implantation failure (RIF...

Status: Not yet recruiting

Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment

This will be an exploratory, prospective, randomized, open-label and controlled trial to evaluate the potential benefit of r-hFSH:r-hLH 2:1 co-treatment starting from COS D1 versus r-hFSH alone in patients aged 35 to 40 under ovarian stimulation treatment. After signing informed consent form (ICF), all eligible participants will be randomly assigned in a 1:1 ratio to either treatment or control group, and GnRH antagonist protocol will be used in both treatment and control groups.

Participants needed: 300
Trial details
Phase: Phase 4Age: 35-40Biological sex: FemaleType: InterventionalSponsor: Nanjing UniversityUpdated: Aug 27, 2024Locations: 1
Eligibility criteria

Age 35 to 40 (including 40) [+5]

Contraindications to ART treatment [+5]

Status: Recruiting

Umbilical Cord Artery-derived Perivascular Stem Cells for the Critical Limb Ischemia Therapy

This clinical trial included 2 periods. During the first period, it was a single arm study to explore the safety of umbilical cord artery-derived stem cells (UCA-PSCs) in the treatment of patients with critical limb ischemia (CLI). During the second perid, it was a single-center, randomized, controlled prospective study to determine the efficacy of the UCA-PSCs treatment. Those who had CLI were enrolled in the study.

Participants needed: 40
Trial details
Phase: Early Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Nanjing UniversityUpdated: Dec 18, 2023Locations: 1
Eligibility criteria

Aged between 18 and 80, of any gender; [+6]

Acute ischemic disease of the lower limb(s) occurred within the past 2 weeks, or... [+10]